tbuckley/cabot-search huggingface dataset:
Kinetics of Pituitary ACTH Secretion in Man.
Authors: E. M. Gold
Journal: Annals of Internal Medicine (1963)

s1 April 1963Kinetics of Pituitary ACTH Secretion in Man.E. M. Gold, M.D.E. M. Gold, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-58-4-721_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptACTH is now detectable in peripheral human plasma at concentrations as low as 0.5 mU/ 100 ml, utilizing sensitive bioassay techniques currently available. Normal resting levels of ACTH in man range from less than 0.5 to 1.2 mU/100 ml at plasma corticosteroid (PSC) concentrations of 10 to 20 μg/100 ml. Acute myocardial infarction and hypoglycemia, while associated with three- to sixfold increases in PSC, produce little change in plasma ACTH. Only slight rises in circulating ACTH titers, amounting to less than 0.5 mU/100 ml, apparently suffice to elevate PSC levels markedly. The lowest rate of pituitary ACTH secretion required to... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, Calif. (CI) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1963Volume 58, Issue 4Page: 721-721KeywordsAcute myocardial infarctionAdrenocorticotropic hormoneAttentionBioassays and physiological analysisBlood plasmaHypoglycemia Issue Published: 1 April 1963 PDF DownloadLoading ...
Pseudoxanthoma elasticum-like papillary dermal elastolysis: report of four Japanese cases and an immunohistochemical study of elastin and fibrillin-1
Authors: None Ohnishi, None Tajima, None Ishibashi, None Inazumi, None Sasaki, None Sakamoto
Journal: British Journal of Dermatology (1998)

We report four patients with pseudoxanthoma elasticum‐like papillary dermal elastolysis (PDE). Multiple small papules on the neck, clinically resembling pseudoxanthoma elasticum, and loss of the elastic fibre network in the papillary dermis were found in each case. Immunohistochemical staining for elastin and fibrillin‐1 in one patient demonstrated the disappearance of elastin and fibrillin‐1 in the papillary dermis. Site‐matched normal skins of the elderly showed intact elastin but a lack of fibrillin‐1 in the papillary dermis. The younger normal skins revealed intact elastin and fibrillin‐1. The results suggest that fibrillin‐1 is absent from the papillary dermis of the normal‐appearing neck skin of the elderly and that the primary defect in PDE may be in elastin rather than in fibrillin‐1.
IT-14 * MESENCHYMAL GLIOMA STEM CELL EXPRESS ICOSL
Authors: R. Iwata, A. Asai, H. Oshige, K. Yoshimura, M. Nonaka, I. Nakano
Journal: Neuro-Oncology (2014)

Human glioblastoma is the most aggressive human primary brain tumor and is currently incurable. Immunitherapies have the pontential to target glioma and glioma stem cells (GSCs) that are resistant to conventional thepies. We previously identified and characterized two mutually exclusive GSC subtypes with distinct dysregulated signaling pathways. Analysis of mRNA profiles distinguished proneural (PN) from mesenchymal (Mes) GSCs and revealed a pronounced correlation with the corresponding PN or Mes HGGs. Here we show the expression of Inducible costimulator-ligand (ICOSL) by glioma cells in vitro and in vivo. We identified that Mes GSCs specificaly expressd ICOSL, however, PN GSCs did not express it. Further, immunohistochemical analysis of human brain tumors demonstrates the expression of ICOSL around the vessels. ICOSL is a member of the B7 family of costimulatory molecules related to CD80/CD86, regulates CD4 as well as CD8 T-cell responses via interaction with its receptor, ICOS, on activated T cells. ICOSL could be a novel target for immunotherapy.
Single Photon Emission Computed Tomography with Tc-99m Glucoheptonate and 1-123 lodoamphetamine in Cerebral Infarction
Authors: ROGER F. UREN, PHILIPPE L. MAGISTRETTI, HENRY D. ROYAL
Journal: Clinical Nuclear Medicine (1982)

UREN, ROGER F. M.B., F.R.A.C.P.; MAGISTRETTI, PHILIPPE L. M.D.; ROYAL, HENRY D. M.D. Author Information
Possible new test for detecting men at risk of prostate cancer
Authors: A. Berger
Journal: BMJ (1998)

Researchers in North America have discovered that measuring plasma concentrations of insulin-like growth factor-1 could help to identify men who are at high risk of developing prostate cancer. The research may also offer a clue to explain why some prostate cancers develop more aggressively than others ( Science 1998;279:563-5).

IGF-1 is a hormone produced in the liver that both stimulates cell growth and inhibits natural cell death (apoptosis) and is critical for normal biological development and growth. High concentrations of IGF-1 encourage a rapid turnover of cells, which in turn increases the risk of a random malignant transformation of these cells into a cancer. Dr June Chan, from the Harvard School of Public Health in Boston, and her colleagues worked on the hypothesis that as IGF-1 acts on the epithelial cells of the prostate gland, men with high circulating concentrations of IGF-1 may be at higher risk of developing prostate cancer than men with lower concentrations.

To test this theory, the team looked at men who are currently participating in the physicians' health study and identified all those who had developed prostate cancer since entering the study in 1982. They found that for 152 of these men they had enough frozen plasma left to measure …
Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model.
Authors: A V Kaplan, L L Leung, W H Leung, G W Grant, I R McDougall, T A Fischell
Journal: Circulation (1991)

Platelet deposition at the site of injury caused by balloon angioplasty is associated with acute closure and restenosis.In a new ex vivo whole artery angioplasty model, we examined the roles of thrombin inhibition with D-Phe-Pro-ArgCH2Cl (PPACK) and inhibition of the platelet membrane fibrinogen receptor glycoprotein IIb/IIIa (GPIIb/IIIa) with monoclonal antibody 7E3 on platelet deposition at the site of balloon injury. Fresh rabbit aortas were mounted in a perfusion chamber. One half of the mounted arterial segment was dilated with a standard angioplasty balloon catheter and the uninjured half served as the control segment. The vessels were perfused with human blood at physiological pressure and shear rates of 180-250 second-1 for 30 minutes. Platelet deposition was measured using 111In-labeled platelets and scanning electron microscopy. With heparin (2 units/ml) anticoagulation, 8.2 +/- 2.2 x 10(6) platelets/cm2 were deposited at the site of balloon injury compared with 0.7 +/- 0.2 x 10(6) platelets/cm2 on uninjured segments (p less than 0.02, n = 7). PPACK was tested at a concentration (10 microM) that totally inhibited platelet aggregation in response to thrombin. 7E3 was tested at a concentration (10 micrograms/ml) that totally inhibited platelet aggregation. Platelet deposition at the site of balloon injury was reduced 47% by PPACK and 70% by 7E3 compared with heparin.At shear rates seen in nonstenotic coronary arteries, PPACK and 7E3 are more effective than heparin in reducing platelet deposition at the site of balloon injury. The significant inhibition of platelet deposition by PPACK demonstrates the importance of heparin-resistant thrombin in platelet thrombus formation. The 7E3 results suggest that approximately 70% of platelet deposition at the site of balloon injury is GPIIb/IIIa dependent and that the remaining 30% results from non-GPIIb/IIIa-mediated platelet-subendothelial adhesion. Finally, the ex vivo whole artery system is a useful model for studying platelet-vessel wall interactions under physiologically defined parameters.
Clinical Subtypes and Molecular Characteristics of Serrated Polyposis Syndrome
Authors: Carla Guarinos, Cristina Sánchez–Fortún, María Rodríguez–Soler, Lucía Pérez–Carbonell, Cecilia Egoavil, Miriam Juárez, Anna Serradesanferm, Luis Bujanda, Fernando Fernández–Bañares, Joaquín Cubiella, Luisa de–Castro, Ana Guerra, Elena Aguirre, Alberto Herreros–de–Tejada, Xavier Bessa, Maite Herráiz, José–Carlos Marín–Gabriel, Judith Balmaña, Miriam Cuatrecasas, Francesc Balaguer, Antoni Castells, José–Luis Soto, Cristina Alenda, Artemio Payá, Rodrigo Jover
Journal: Clinical Gastroenterology and Hepatology (2013)
High-Risk Medical Devices
Authors: Joseph S. Ross
Journal: JAMA Internal Medicine (2015)

Rohan Khera, MD; Peter Cram, MD, MBA; Xin Lu, MS; Ankur Vyas, MD, MS; Alicia Gerke, MD, MS; Gary E. Rosenthal, MD; Phillip A. Horwitz, MD; Saket Girotra, MD, SM
DELAYED HYPERSENSITIVITY
Authors: Jonathan W. Uhr, Matthew Scharff
Journal: The Journal of Experimental Medicine (1960)

The capacity to develop the delayed type of hypersensitivity to diphtheria toxoid and ovalbumin may persist in guinea pigs and rabbits that have received doses of x-ray sufficient to eliminate a detectable antibody response. Larger doses of x-irradiation can prevent development of delayed-type hypersensitivity in rabbits.
RAID Teams to Respond to Terrorism Threat
Authors: Phil Gunby
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antithrombotic potential of dihomo-gamma-linolenic acid in man.
Authors: P B Kernoff, A L Willis, K J Stone, J A Davies, G P McNicol
Journal: BMJ (1977)

The effects of orally ingested dihomo-gamma-linolenic acid (DHLA), the natural biosynthetic precursor of prostaglandin E1 (PGE1), were assessed in human volunteers. Single doses of DHLA (0.1--2g) increased the proportion of DHLA relative to arachidonic acid in plasma and platelets and also increased the ex-vivo capacity of platelets to produce PGE1 and PGE2. More pronounced effects were observed during sustained treatment (five days to four weeks) when DHLA also accumulated in red cell membranes. These biochemical changes were accompanied by potentially antithrombotic changes in haemostatic function. The most common effect, which was consistently detected after 0.1-g single doses of DHLA or its methyl ester, was a decrease in plasma heparin-neutralising activity. Inhibition of platelet aggregation induced by adenosine diphosphate was also detected, though this was generally less pronounced. Sustained treatment in one subject also produced definite inhibition of ristocetin-induced platelet aggregation. There was only one possible adverse effect--a transient cough in a subject with a history of asthma. DHLA therefore seems to have considerable potential as an agent for preventing and treating human thromboembolic disease.
Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor
Authors: Takami Sato, David J. Eschelman, Carin F. Gonsalves, Mizue Terai, Inna Chervoneva, Peter A. McCue, Jerry A. Shields, Carol L. Shields, Akira Yamamoto, David Berd, Michael J. Mastrangelo, Kevin L. Sullivan
Journal: Journal of Clinical Oncology (2008)

Purpose We conducted a phase I study to investigate the feasibility and safety of immunoembolization with granulocyte-macrophage colony-stimulating factor (GM-CSF; sargramostim) for malignant liver tumors, predominantly hepatic metastases from patients with primary uveal melanoma. Patients and Methods Thirty-nine patients with surgically unresectable malignant liver tumors, including 34 patients with primary uveal melanoma, were enrolled. Hepatic artery embolization accompanied an infusion of dose-escalated GM-CSF (25 to 2,000 μg) given every 4 weeks. Primary end points included dose-limiting toxicity and maximum tolerated dose (MTD). Patients who completed two cycles of treatments were monitored for hepatic antitumor response. Survival rates of patients were also monitored. Results MTD was not reached up to the dose level of 2,000 μg, and there were no treatment-related deaths. Thirty-one assessable patients with uveal melanoma demonstrated two complete responses, eight partial responses, and 10 occurrences of stable disease in their hepatic metastases. The median overall survival of intent-to-treat patients who had metastatic uveal melanoma was 14.4 months. Multivariate analyses indicated that female sex, high doses of GM-CSF (≥ 1,500 μg), and regression of hepatic metastases (complete and partial responses) were correlated to longer overall survival. Moreover, high doses of GM-CSF were associated with prolonged progression-free survival in extrahepatic sites. Conclusion Immunoembolization with GM-CSF is safe and feasible in patients with hepatic metastasis from primary uveal melanoma. Encouraging preliminary efficacy and safety results warrant additional clinical study in metastatic uveal melanoma.
On Real-Time Estimates of Blood Glucose Levels
Authors: Oliver J. Gibson, Andrew J. Farmer, Patrick E. McSharry, Lionel Tarassenko
Journal: Diabetes Care (2007)

Trevino (1) has misunderstood our description of the feedback about blood glucose levels offered to patients in our trial of a real-time telemedicine system (2). He has also attributed a quotation from an article by Bode et al. (3) to our report (2). Trevino calls for the use of better statistical methods to deal with temporal correlations between the repeated glucose values used in real-time monitoring. While we have sympathy with this message, …
Generation of Epstein-Barr virus–specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
Authors: Biagio De Angelis, Gianpietro Dotti, Concetta Quintarelli, Leslie E. Huye, Lan Zhang, Ming Zhang, Fabrizio Pane, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Barbara Savoldo
Journal: Blood (2009)
Death During Use of Schleich Solution.
Authors: R. M. Stone
Journal: JAMA (1900)

Omaha, Neb., July 22, 1900. <h3>To the Editor:</h3> —Since Dr. Willy Meyer called the attention of the American profession to the Schleich solution in 1897, I have been a careful student of its use and have had opportunity for my studies in my work as anesthetist of the Presbyterian Hospital and while giving it, upon invitation, in the Presbyterian Hospital in Chicago for Dr. Etheridge, Dr. Stehman and Dr. Hamilton, in Mercy Hospital for Dr. Murphy, in the Dental College for Dr. Brophy, and in Cook County Hospital for Dr. Burton, and in my own city for many of our surgeons. I have been deeply impressed with its qualities, its superiority and its comparative safety. I have never felt that it was a safe anesthetic, for we have none, nor can we ever have one. It becomes my duty to report a death from its use, and it is the
Pathophysiologic Importance of E– and L–Selectin for Neutrophil–Induced Liver Injury During Endotoxemia in Mice
Authors: Judy A. Lawson, Alan R. Burns, Anwar Farhood, Mary Lynn Bajt, Robert G. Collins, Wayne C. Smith, Hartmut Jaeschke
Journal: Hepatology (2000)

Neutrophils can cause parenchymal cell injury in the liver during ischemia-reperfusion and endotoxemia. Neutrophils relevant for the injury accumulate in sinusoids, transmigrate, and adhere to hepatocytes. To investigate the role of E- and L-selectin in this process, C3Heb/FeJ mice were treated with 700 mg/kg galactosamine and 100 microgram/kg endotoxin (Gal/ET). Immunogold labeling verified the expression of E-selectin on sinusoidal endothelial cells 4 hours after Gal/ET injection. In addition, Gal/ET caused up-regulation of Mac-1 (CD11b/CD18) and shedding of L-selectin from circulating neutrophils. Gal/ET induced hepatic neutrophil accumulation (422 +/- 32 polymorphonuclear leukocytes [PMN]/50 high power fields [HPF]) and severe liver injury (plasma alanine transaminase [ALT] activities: 4,120 +/- 960 U/L; necrosis: 44 +/- 3%) at 7 hours. Treatment with an anti-E-selectin antibody (3 mg/kg, intravenously) at the time of Gal/ET administration did not significantly affect hepatic neutrophil accumulation and localization. However, the anti-E-selectin antibody significantly attenuated liver injury as indicated by reduced ALT levels (-84%) and 43% less necrotic hepatocytes. In contrast, animals treated with an anti-L-selectin antibody or L-selectin gene knock out mice were not protected against Gal/ET-induced liver injury. However, E-, L-, and P-selectin triple knock out mice showed significantly reduced liver injury after Gal/ET treatment as indicated by lower ALT levels (-65%) and reduced necrosis (-68%). Previous studies showed that circulating neutrophils of E-selectin-overexpressing mice are primed and activated similar to neutrophils adhering to E-selectin in vitro. Therefore, we conclude that blocking E-selectin or eliminating this gene may have protected against Gal/ET-induced liver injury in vivo by inhibiting the full activation of neutrophils during the transmigration process.
Apical hypertrophic cardiomyopathy: evaluation by noninvasive and invasive techniques in 23 patients.
Authors: G Keren, B Belhassen, J Sherez, H I Miller, R Megidish, D Berenfeld, S Laniado
Journal: Circulation (1985)

Over a 3 year period we evaluated 23 patients (16 men, seven women) with apical hypertrophic cardiomyopathy by noninvasive and invasive methods. Sixteen patients had chest pain. In 17, results of cardiovascular examination were normal. The electrocardiogram showed precordial inverted T waves in all patients and these were of mild-to-moderate amplitude (less than 10 mm) in 18 and giant (greater than 10 mm) in five. M mode echocardiography revealed a typical pattern of contraction and relaxation in the apical region of the left ventricle that was associated with significant hypertrophy. These findings were confirmed by two-dimensional echocardiography. Systolic anterior motion of the mitral valve was not observed nor was there any evidence of obstruction of the left ventricular outflow tract. Results of Doppler echocardiographic study of the mitral and aortic flow were normal in all patients but one who had mild mitral insufficiency. Radionuclide studies of 14 patients revealed a mean left ventricular ejection fraction of 66 +/- 6% (range 55% to 79%), with normal left ventricular contraction in all patients but two with apical hypokinesis. In all six patients who underwent catheterization a characteristic appearance of the left ventricle at end-systole as well as abnormal end-diastolic contour were noted on the left ventricular angiogram, but the "ace of spades" configuration was seen in only one. We conclude that the 23 patients studied form a homogeneous group of individuals with nonobstructive apical hypertrophic cardiomyopathy, which differs in many respects from cardiomyopathies reported by other investigators.
The Digital Camera as a Clinical Tool
Authors: John J. Stern
Journal: Annals of Internal Medicine (2005)

Letters18 October 2005The Digital Camera as a Clinical ToolJohn J. Stern, MDJohn J. Stern, MDFrom The Pennsylvania Hospital, Philadelphia, PA 19107.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-8-200510180-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I recently entered the modern era and bought a pocket-sized digital camera. In the process, I discovered a unique and powerful tool for teaching patients about their own illnesses.As an infectious disease specialist, I have relied for years on a single-lens reflex camera to record images of unusual and interesting rashes, lesions, computed tomography (CT) scans, and other radiologic studies and have used these images primarily to educate medical students, housestaff, and colleagues. I would show slides in clinical conferences, formal presentations, clinical pathologic conferences, and publications. When I wanted a patient to see a film ... Author, Article, and Disclosure InformationAffiliations: From The Pennsylvania Hospital, Philadelphia, PA 19107.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 18 October 2005Volume 143, Issue 8Page: 619-620KeywordsComputed axial tomographyEye diseasesHealth care providersInfectious diseasesKidneysLesionsPhotographyRashesReflexesUreter ePublished: 18 October 2005 Issue Published: 18 October 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Sudden death in epilepsy: of mice and men
Authors: Daniel Friedman, Janice Chyou, Orrin Devinsky
Journal: Journal of Clinical Investigation (2013)

A 20-year-old man with intellectual disability and intractable multifocal epilepsy presented to a neurologist for further evaluation and management. His seizures began at 4 months, the night after his first DPT vaccine, and he continued to have frequent tonic-clonic seizures throughout his life. Several weeks after his visit, he was found facedown on the floor, dead, by his family. His autopsy was unremarkable, but genetic testing revealed a frame shift mutation in SCN1A, consistent with severe myoclonic epilepsy of infancy (Dravet syndrome).
Effect of electromagnetic field exposure on chemically induced differentiation of friend erythroleukemia cells.
Authors: G Chen, B L Upham, W Sun, C C Chang, E J Rothwell, K M Chen, H Yamasaki, J E Trosko
Journal: Environmental Health Perspectives (2000)

Whether exposure of humans to extremely low frequency electromagnetic fields (ELF-EMF) can cause cancer is controversial and therefore needs further research. We used a Friend erythroleukemia cell line that can be chemically induced to differentiate to determine whether ELF-EMF could alter proliferation and differentiation in these cells in a manner similar to that of a chemical tumor promoter. Exposure of this cell line to 60 Hz ELF-EMF resulted in a dose dependent inhibition of differentiation, with maximal inhibition peaking at 40% and 40 mG (4 microT). ELF-EMF at 10 mG (1.0 microT) and 25 mG (2.5 microT) inhibited differentiation at 0 and 20%, respectively. ELF-EMF at 1.0 (100) and 10.0 G (1,000 microT) stimulated cell proliferation 50% above the sham-treated cells. The activity of telomerase, a marker of undifferentiated cells, decreased 100[times] when the cells were induced to differentiate under sham conditions, but when the cells were exposed to 0.5 G (50 microT) there was only a 10[times] decrease. In summary, ELF-EMF can partially block the differentiation of Friend erythroleukemia cells, and this results in a larger population of cells remaining in the undifferentiated, proliferative state, which is similar to the published results of Friend erythroleukemia cells treated with chemical-tumor promoters.